

## Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperazine and pyronaridine

Aurélie Pascual, Marilyn Madamet, Sébastien Briolant, Tiphaine Gaillard, Rémy Amalvict, Nicolas Benoit, Dominique Travers, Bruno Pradines

► **To cite this version:**

Aurélie Pascual, Marilyn Madamet, Sébastien Briolant, Tiphaine Gaillard, Rémy Amalvict, et al.. Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperazine and pyronaridine. Malaria Journal, BioMed Central, 2015, 14 (49), 10.1186/s12936-015-0586-6 . hal-01221323

**HAL Id: hal-01221323**

**<https://hal-amu.archives-ouvertes.fr/hal-01221323>**

Submitted on 27 Oct 2015

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

RESEARCH

Open Access

# Multinormal *in vitro* distribution of *Plasmodium falciparum* susceptibility to piperavaquine and pyronaridine

Aurélien Pascual<sup>1,2,3</sup>, Marilyn Madamet<sup>2,3,4</sup>, Sébastien Briolant<sup>1,2,5,6</sup>, Tiphaine Gaillard<sup>1,7</sup>, Rémy Amalvict<sup>1,2,3,4</sup>, Nicolas Benoit<sup>2,3,4</sup>, Dominique Travers<sup>1,2,3</sup>, Bruno Pradines<sup>1,2,3,8\*</sup> and the French National Reference Centre for Imported Malaria Study Group

## Abstract

**Background:** In 2002, the World Health Organization recommended that artemisinin-based combination therapy (ACT) be used to treat uncomplicated malaria. Dihydroartemisinin-piperavaquine and artesunate-pyronaridine are two of these new combinations. The aim of the present work was to assess the distribution of the *in vitro* values of pyronaridine (PND) and piperavaquine (PPQ) and to define a cut-off for reduced susceptibility for the two anti-malarial drugs.

**Methods:** The distribution and range of the 50% inhibitory concentration values (IC<sub>50</sub>) of PND and PPQ were determined for 313 isolates obtained between 2008 and 2012 from patients hospitalized in France for imported malaria. The statistical Bayesian analysis was designed to answer the specific question of whether *Plasmodium falciparum* has different phenotypes of susceptibility to PND and PPQ.

**Results:** The PND IC<sub>50</sub> values ranged from 0.6 to 84.6 nM, with a geometric mean of 21.1 ± 16.0 nM (standard deviation). These values were classified into three components. The PPQ IC<sub>50</sub> values ranged from 9.8 to 217.3 nM, and the geometric mean was 58.0 ± 34.5 nM. All 313 PPQ values were classified into four components. Isolates with IC<sub>50</sub> values greater than 60 nM or four-fold greater than 3D7 IC<sub>50</sub> are considered isolates that have reduced susceptibility to PND and those with IC<sub>50</sub> values greater than 135 nM or 2.3-fold greater than 3D7 IC<sub>50</sub> are considered isolates that have reduced susceptibility to PPQ.

**Conclusion:** The existence of at least three phenotypes for PND and four phenotypes for PPQ was demonstrated. Based on the cut-off values, 18 isolates (5.8%) and 13 isolates (4.2%) demonstrated reduced susceptibility to PND and PPQ, respectively.

**Keywords:** Malaria, *Plasmodium falciparum*, Anti-malarial, *In vitro*, Resistance, Piperavaquine, Pyronaridine

## Background

Over the past 20 years, many strains of *Plasmodium falciparum* have become resistant to chloroquine and other anti-malarial drugs. In 2002, the World Health Organization (WHO) recommended that artemisinin-based combination therapy (ACT) be used to treat all cases of uncomplicated malaria. The following combinations have been evaluated:

artesunate-sulphadoxine-pyrimethamine, artesunate-amodiaquine, artemether-lumefantrine, artesunate-mefloquine, artesunate-chlorproguanil-dapsone and, more recently, artesunate-pyronaridine and dihydroartemisinin-piperavaquine. Most of these combinations are available as fixed-dose co-formulations that are convenient, facilitate improved adherence and help prevent misuse.

Dihydroartemisinin-piperavaquine (DP) (Artekin<sup>®</sup>, Duo-Cotecxin<sup>®</sup>, Eurartesim<sup>®</sup>) is a new ACT that is administered as single daily dose for three days. It has been demonstrated to be well tolerated and highly effective for the treatment of uncomplicated malaria in Asia [1,2] and for the treatment of uncomplicated *P. falciparum* malaria in

\* Correspondence: bruno.pradines@free.fr

<sup>1</sup>Unité de Parasitologie, Département d'Infectiologie de Terrain, Institut de Recherche Biomédicale des Armées, Marseille, France

<sup>2</sup>Aix Marseille Université, Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, UM 63, CNRS 7278, IRD 198, Inserm 1095, Marseille, France

Full list of author information is available at the end of the article

Africa [3-6]. DP may also have a better post-treatment prophylactic effect than does artemether-lumefantrine [7-9] and artesunate-amodiaquine [10]. Since 2012, DP has been available for the treatment of uncomplicated falciparum malaria in France. DP has also been demonstrated to be effective for the treatment of *Plasmodium vivax* malaria [11]. However, the emergence of *P. falciparum* resistance to DP, manifested as delayed parasite clearance following the treatment, has developed in Cambodia and Vietnam [12-14].

The piperazine (PPQ) susceptibility of *P. falciparum* isolates has been assessed in studies with isolates from Africa (geometric mean  $IC_{50}$  = 81.3 nM and 66.8 nM) [15,16], Cameroon (39 nM) [17], Kenya (from 41.9 to 50 nM) [18-20], Niger (24.2 nM) [21], Ghana (28.3 nM) [22], Uganda (6.1 nM) [23], the China-Myanmar border (28.4 nM) [24], the Thai-Burmese border (49 nM) [25], Cambodia (22 nM) [26], Indonesia (21.8 nM) [27], and Papua New Guinea [28].

The pyronaridine-artesunate combination (Pyramax®) is one of the latest artemisinin-based combinations and is currently under development by the not-for-profit organization Medicines for Malaria Venture (Geneva, Switzerland) and the pharmaceutical company Shin Poong Pharmaceuticals (Seoul, Republic of Korea) for the treatment of uncomplicated *P. falciparum* malaria and for the blood stages of *P. vivax* malaria. Pyramax® has recently completed phase III trials in humans. A five-day regimen of pyronaridine (PND) alone (total dose = 1,800 mg) produced a better cure rate than did artesunate, artemether or mefloquine used alone in the same conditions in Thailand [29]. The efficacy of PND-artesunate was not inferior to that of artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in Africa and Southeast Asia [30,31]. PND-artesunate had a better efficacy than did mefloquine-artesunate in Cambodia [32].

The PND *in vitro* susceptibility was previously assessed in *P. falciparum* strains (1.9 to 47.8 nM and 15 to 49 nM, respectively) [33,34] and in isolates from Africa (geometric mean = 19.9 nM) [16], Cameroon (3.58 nM) [35], Gabon (3.0 nM and 1.87 nM) [36,37], Kenya (13.5 nM) [19], Niger (9.8 nM) [21], Senegal (3.8 nM and 4.52 nM) [38,39], Indonesia (1.92 nM) [40], and in isolates from patients in Thailand that were cured with PND (15.7 nM) or that recrudesced after PND treatment (23.0 nM) [29]. In addition, PND is effective *in vitro* against *P. vivax* isolates (2.58 nM) [40].

The early detection of resistance to PPQ and PND requires the establishment of the baseline parasite chemosusceptibility of current isolates from regions of endemicity. The aim of the present work was to determine the distribution and range of the 50% inhibitory concentrations ( $IC_{50}$ ) of PPQ and PND for 313 imported malaria isolates from Africa and to determine the cut-off

values for *in vitro* reduced susceptibility to these two drugs.

## Methods

### Patients and sample collection

In total, 313 *P. falciparum* isolates were collected between April 2008 and August 2012 from patients hospitalized in France with imported malaria from a malaria-endemic country (Angola, Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Comoros, Congo, Ivory Coast, Gabon, Gambia, Ghana, Guinea, Madagascar, Mali, Mauritania, Mozambique, Niger, Senegal, Togo, Zambia). Informed consent was not required for this study because the sampling procedures and testing are part of the French national recommendations for the care and surveillance of malaria. Venous blood samples were collected in Vacutainer® ACD tubes (Becton Dickinson, Rutherford, NJ, USA) before treatment and were transported at 4°C from French hospitals located in Aix en Provence, Bordeaux, Chambéry, Frejus, Grenoble, Lyon, Marseille, Metz, Montpellier, Nice, Nîmes, Pau, Toulon, Toulouse, and Valence to the Institute of Biomedical Research of the French Army (IRBA) in Marseille within 72 hours of collection. A Case Report Form was provided at the same time, either as a paper copy or electronically.

Thin blood smears were stained using a RAL® kit (Réactifs RAL, Paris, France) and were examined to determine the *P. falciparum* density and confirm mono-infection. Parasitized erythrocytes were washed three times with RPMI 1640 medium (Invitrogen, Paisley, UK), buffered with 25 mM HEPES and 25 mM  $NaHCO_3$ . If the parasitaemia exceeded 0.5%, the infected erythrocytes were diluted to 0.5% with uninfected erythrocytes (human blood type A+) and re-suspended in RPMI 1640 medium supplemented with 10% human serum (Abcys S.A. Paris, France) for a final haematocrit of 1.5%. The susceptibility of the 313 isolates was assessed without culture adaptation.

### Drugs

PPQ and PND were obtained from Shin Poong Pharm Co. (Seoul, Korea). PPQ was first dissolved in methanol and then diluted in water to obtain final concentrations ranging from 0.8 to 1,000 nM. PND was dissolved and diluted in water to obtain concentrations ranging from 0.15 to 100 nM.

Batches of plates were tested and validated using the chloroquine-susceptible strain 3D7 (isolated in West Africa; obtained from MR4, VA, USA) in three to six independent experiments using the conditions described below. The two strains were synchronized twice with sorbitol before use [41], and clonality was verified every 15 days through PCR genotyping of the polymorphic genetic markers *msp1* and *msp2* and microsatellite loci [42,43]; additionally, clonality was verified each year by

an independent laboratory from the Worldwide Anti-malarial Resistance Network (WWARN).

### Ex vivo assay

For *ex vivo* isotopic microtests, 200  $\mu$ l/well of the suspension of parasitized red blood cells (final parasitaemia, 0.5%; final haematocrit, 1.5%) were distributed in 96-well plates pre-dosed with anti-malarial drugs. Parasite growth was assessed by adding 1  $\mu$ Ci of tritiated hypoxanthine with a specific activity of 14.1 Ci/mmol (Perkin-Elmer, Courtaboeuf, France) to each well at time zero. The plates were then incubated for 42 hours in controlled atmospheric conditions that consisted of 10% O<sub>2</sub>, 5% CO<sub>2</sub> and 85% N<sub>2</sub> at 37°C with a humidity of 95%. Immediately after incubation, the plates were frozen and then thawed to lyse the erythrocytes. The contents of each well were collected on standard filter microplates (Unifilter GF/B; Perkin-Elmer) and washed using a cell harvester (Filter-Mate Cell Harvester; Perkin-Elmer). The filter microplates were dried, and 25  $\mu$ l of scintillation cocktail (Microscint O; Perkin-Elmer) was placed in each well. Radioactivity incorporated in nucleotides by the parasites was measured with a scintillation counter (Top Count; Perkin-Elmer).

The drug concentration able to inhibit 50% of the parasite growth (IC<sub>50</sub>) was assessed by the drug concentration corresponding to 50% of the incorporation of tritiated hypoxanthine by the parasite in the drug-free control wells. The IC<sub>50</sub> value was determined using a non-linear regression analysis of log-based dose-response curves (Riasmart, Packard, Meriden, USA).

### Statistical analysis

The statistical analysis was designed to answer the specific question of whether *P. falciparum* has different PPQ and PND susceptibility phenotypes. A heterogeneous population of IC<sub>50</sub> values was observed; therefore, the data were assumed to represent a univariate Gaussian mixture with *k* components. Each observation was assumed to originate from one of the *k* components, and the label of the group from which each observation arose was unknown. The unknowns of the model were the number of components, the means, variances and weights of the different components, and the vector of allocations of the observations. The analysis was performed in two steps. First, reversible jump Monte Carlo Markov Chains (RJMCMC) [44] samplers were used to choose a suitable number of components *k*, and the present algorithm followed the recommendations of Cappé *et al.* [45]. After a relevant number of components was chosen, standard Gibbs samplers were run to obtain estimates of the model parameters and to classify the observations [46]. Because of the 'label-switching' problem that is due to the symmetry in the likelihood of the model parameters, the mixture components should be labelled before making an inference regarding the

parameters [47]. The classical ordering constraint, which was biologically relevant here, was used. The algorithms were run for 100,000 burn-in iterations and 20,000 post-burn-in iterations. These numbers were assumed to be sufficient to obtain reliable results. Moreover, each algorithm was run three times to verify that the results obtained in two different runs were similar and that there was no convergence problem [44].


### Results

The PND IC<sub>50</sub> values ranged from 0.6 to 84.6 nM (Figure 1). The geometric mean was 21.1  $\pm$  16.0 nM (standard deviation). The average parameter estimates for the IC<sub>50</sub> values by year are given in Table 1. There was no significant difference in the PND responses between the five years (*p* = 0.9416, Kruskal-Wallis rank sum test). In addition, there was no significant difference in the responses to PND against the strain 3D7, which was used as a control for the plate batches (*p* = 0.8904).

The triple normal distribution model for PND is represented in Figure 2. The parameter estimates for the three-component mixture model, including the number of isolates in each normal distribution, the mean of the IC<sub>50</sub> values and the standard deviation (SD) for each distribution, are summarized in Table 2.

The cut-off value for *in vitro* reduced susceptibility to PND was estimated using the arithmetic mean plus two SDs of the IC<sub>50</sub>s of the 309 isolates and was set at 57.7 nM. Isolates with an IC<sub>50</sub> greater than 60 nM were considered to display reduced susceptibility to PND *in vitro*. Eighteen isolates (5.8%) displayed reduced susceptibility to PND *in vitro*.

The PPQ IC<sub>50</sub> values ranged from 9.8 to 217.3 nM (Figure 1). The geometric mean was 58.0  $\pm$  34.5 nM (standard deviation). The average parameter estimates for the IC<sub>50</sub> values by year are given in Table 3. There was a significant difference in the PPQ responses



**Figure 1** Piperaquine and pyronaridine median 50% inhibitory concentrations (IC<sub>50</sub> values in nM) of 313 *Plasmodium falciparum* isolates.

**Table 1 Statistical analysis of the 309 pyronaridine (PND) IC<sub>50</sub> values by year**

Year	IC <sub>50</sub> number	Mean (nM)	SD	IC <sub>50</sub> min	IC <sub>50</sub> max
2008	60	21.4	14.5	3.8	67.4
2009	92	21.9	15.2	3.2	76.1
2010	88	19.4	15.7	0.6	80.0
2011	47	23.0	18.3	6.2	75.3
2012	22	21.1	19.3	9.1	84.6
Total	309	21.1	16.0	0.6	84.6

SD: standard deviation.


between the five years ( $p < 0.0001$ , Kruskal-Wallis rank sum test). However, there was no significant difference in the responses to PPQ against the strain 3D7, which was used as a control for the plate batches ( $p = 0.6909$ ).

The quadruple normal distribution model for PPQ is presented in Figure 3. The parameter estimates for the quadruple-component mixture model, including the number of isolates in each normal distribution, the mean of the IC<sub>50</sub> values and the standard deviation for each distribution, are summarized in Table 4.

The cut-off for *in vitro* reduced susceptibility to PPQ was estimated using the arithmetic mean plus 2 SDs of the IC<sub>50</sub>s of the 313 isolates and was found to be 135.4 nM. Isolates with an IC<sub>50</sub> greater than 135 nM were considered to be isolates with reduced susceptibility to PPQ *in vitro*. Thirteen isolates (4.2%) displayed reduced susceptibility to PPQ *in vitro*.

**Discussion**

The early detection of resistance to PPQ and PND requires that the baseline parasite chemosensitivity of current isolates from regions of endemicity be established.



**Table 2 Parameter estimates for the three-component mixture model for the pyronaridine (PND) distribution of the 309 Plasmodium falciparum isolates**

Component	Isolates number	Proportion (%)	IC <sub>50</sub> mean (nM)	Standard deviation
A	182	58.9	15.1	5.6
B	96	31.1	33.9	5.3
C	31	10.0	59.7	12.2

Maximizing the efficacy and longevity of drugs as a tool to control malaria will critically depend on pursuing intensive research into identifying *in vitro* markers and implementing *in vitro* and *in vivo* surveillance programmes, such as those championed by WWARN [48,49]. In this context, there is a need to identify *in vitro* and molecular markers that predict PPQ and PND resistance and can provide an active surveillance method to monitor temporal trends in parasite susceptibility [50,51].


A Bayesian mixture modeling approach was chosen. A Bayesian approach has already been proposed for anti-malarial *in vitro* susceptibilities; it has been used to evaluate the distribution and the cut-off for reduced susceptibility to doxycycline [52,53]. All 309 PND values were classified into three components: component A (IC<sub>50</sub> mean 15.1 nM), component B (IC<sub>50</sub> mean 33.9 nM) and component C (IC<sub>50</sub> mean 59.7 nM). The proportion of isolates in each group was 58.9% for component A, 31.1% for component B and 10.0% for component C. In the previous study on doxycycline, the distribution of the doxycycline IC<sub>50</sub> in a triple normal distribution was independent of the African origin of the isolates (imported isolates from Africa or field isolates from Senegal, Gabon or Congo) [52]. Only the proportion of isolates predicted to belong to each component was dependent on the origin of the isolates.

In the present study, the cut-off for *in vitro* reduced susceptibility to PND was estimated as the geometric mean plus 2 SDs of the IC<sub>50</sub>s of the 309 isolates (57.7 nM). Isolates with an IC<sub>50</sub> greater than 60 nM were considered to be isolates with reduced *in vitro* susceptibility to PND. Eighteen isolates (5.8%) demonstrated reduced susceptibility to PND *in vitro*. These data are consistent

**Table 3 Statistical analysis of the 313 piperazine (PPQ) IC<sub>50</sub> values by year**

Year	IC <sub>50</sub> number	Mean (nM)	SD	IC <sub>50</sub> min	IC <sub>50</sub> max
2008	60	77.8	40.5	20.6	217.3
2009	95	70.6	30.6	14.0	189.0
2010	89	44.0	23.4	11.8	92.3
2011	47	44.6	20.9	11.8	123.0
2012	22	59.7	46.2	9.8	196.0
Total	313	58.0	34.5	9.8	217.3

SD: standard deviation.



with clinical observations of limited failures with PND. One study of isolates in Niger reported that 3% of the isolates displayed *in vitro* resistance to PND, with an estimated cut-off of 20 nM [21].

A cut-off for *in vitro* resistance is defined for a specific methodology. For example, the *in vitro* effects and the IC<sub>50</sub> values for doxycycline are dependent on the time incubation conditions [14-16], on gas conditions, i.e., O<sub>2</sub> and CO<sub>2</sub> [54,55] and on methodology, i.e., isotopic test versus immuno-enzymatic or SYBR green test [56,57]. The incubation time is the condition that interferes significantly with the IC<sub>50</sub> values for doxycycline or other antibiotics [58,59]. The IC<sub>50</sub> values decrease by a factor between 10 to 100 in prolonged exposure to antibiotics. The gas conditions interfere with the IC<sub>50</sub> values for quinolines, such as chloroquine, monodesethyaodiaquine, quinine, mefloquine, or lumefantrine [55,60]. The IC<sub>50</sub> values for quinoline drugs are significantly lower at O<sub>2</sub> > 15% than those at 10% O<sub>2</sub>. Dissolution methods to prepare the stock solutions of anti-malarial drugs can also interfere with IC<sub>50</sub> values. In the present study, the dissolution of PND in water was the same condition as this used in previous work [16,36,37,61]. Using an arbitrarily fixed threshold of resistance could lead to wrong decision making at the

**Table 4** Parameter estimates for the four-component mixture model for the piperazine PPQ) distribution of the 313 *Plasmodium falciparum* isolates

Component	Isolates number	Proportion (%)	IC <sub>50</sub> mean (nM)	Standard deviation
A	136	43.5	35.4	11.4
B	146	46.6	76.7	12.6
C	22	7.0	103.5	20.4
D	9	2.9	175.0	26.2

country level. To reduce the effects of the conditions of the methodology of the *in vitro* test, an IC<sub>50</sub> ratio (IC<sub>50</sub> of clinical isolate/mean IC<sub>50</sub> of 3D7 on the same batch of plates) can be evaluated for each isolate [56]. Another mean is to use a cut-off ratio (resistance cut-off defined for a specific methodology/mean IC<sub>50</sub> of 3D7 tested by the same methodology). Isolates with cut-off ratio greater than four (60/16.7), i.e., isolates with IC<sub>50</sub> four-fold greater than 3D7 IC<sub>50</sub>, are considered to be isolates with reduced *in vitro* susceptibility to PND. Compared to 3D7 IC<sub>50</sub> values, the data obtained with different methodologies can be compared.

All 313 PPQ values were classified into four components: component A (IC<sub>50</sub> mean 35.4 nM), component B (IC<sub>50</sub> mean 76.7 nM), component C (IC<sub>50</sub> mean 103.5 nM), and component D (IC<sub>50</sub> mean 175.0 nM). The proportion of isolates in each group was 43.5% for component A, 46.6% for component B, 7.0% for component C, and 2.9% for component D.

In the present study, PPQ was dissolved in methanol and then diluted in water. In previous works, PPQ was dissolved in methanol and then diluted in water [13,14,24,25], in methanol and hydrochloric acid and then diluted in water [20,62], in dimethyl sulphoxide (DMSO) [27,63] or in 0.5% acid lactic in water [15,28,63-65]. These several dissolution methods to prepare the PPQ stock solutions can interfere with IC<sub>50</sub> values. The cut-off for *in vitro* reduced susceptibility to PPQ was estimated to be the geometric mean plus 2 SDs of the IC<sub>50</sub>s of the 313 isolates (135.4 nM). Isolates with an IC<sub>50</sub> greater than 135 nM or 2.3-fold greater than PPQ IC<sub>50</sub> for 3D7 were considered to be isolates with reduced *in vitro* susceptibility to PPQ. Thirteen isolates (4.2%) met the criteria for reduced susceptibility to PPQ *in vitro*. These data are consistent with previous data from Niger but not from the China-Myanmar border. In Niger, 6% of the isolates were found to be resistant to PPQ *in vitro*, with an estimated cut-off of 150 nM [21]. However, 83% of the isolates from the China-Myanmar border were resistant to PPQ *in vitro* (the cut-off of approximately 15 nM was estimated by a three-fold decrease in susceptibility to PPQ in comparison to the strain 3D7) [24].

There was a significant difference in the PPQ responses among the five years of the study (p < 0.0001, Kruskal-Wallis rank sum test). However, there was no significant difference in the responses to PPQ against 3D7 (geometric mean each year from 2008 to 2012: 56.7 nM, 58.4 nM, 61.0, 57.2 nM, and 62.5 nM; p = 0.6909). This absence of significant difference in the responses of the control strains makes bias due to the methodology unlikely.

The existence of at least three phenotypes for PND and four phenotypes for PPQ was demonstrated. These phenotypes may be associated with different genotypes. Genotyping analysis would be necessary to identify the molecular basis of the susceptibility differences and to

correlate the genetic profiles with the phenotypes. Previous work demonstrated that the doxycycline phenotypes predicted by the Bayesian method were associated with specific genotypes [53,63]. The priority now is to investigate polymorphisms both in the genes that are known to be involved in anti-malarial drug resistance and in new genes for each phenotype.

## Conclusion

The PND and PPQ *in vitro* susceptibility values ranged into three and four components, respectively. Eighteen isolates (5.8%) and 13 isolates (4.2%) demonstrated reduced *in vitro* susceptibility to PND and PPQ, respectively. DP is associated with a longer prophylactic time after treatment compared to the time after artemether-lumefantrine treatment [5,6,64]. However, the gametocyte carriage and malaria transmission to mosquitoes was lower after artemether-lumefantrine treatment [66]. Despite the recent report of frequent DP failures in Cambodia and Vietnam [12-14], DP remains an effective treatment for falciparum malaria in Africa and for *P. vivax* [67-69]. PND-artesunate is effective for the treatment of uncomplicated falciparum malaria in Africa and Southeast Asia [30,31]. PND-artesunate successfully treats artemisinin-resistant *Plasmodium berghei* parasites, while artemether-lumefantrine, artesunate-amodiaquine, artesunate-mefloquine and dihydroartemisinin-piperazine are not effective [70]. Although extended parasite clearance times were indicative of artemisinin resistance, ACT remains important for the treatment of malaria.

## Competing interests

All authors declare that they have no competing interests.

## Authors' contributions

AP, MM, RA, NB, and DT carried out the *ex vivo* evaluation of doxycycline susceptibility. The French National Reference Centre for Imported Malaria Study Group supervised, carried out and coordinated the field collections of patient isolates. BP conceived and coordinated the study. SB, TG and BP analysed the data. AP, MM, SB, TG, and BP drafted the manuscript. All the authors read and approved the final manuscript.

## Acknowledgements

This study was supported by the Institut de Veille Sanitaire (grant number CNR paludisme).

## French National Reference Centre for Imported Malaria Study Group

V Augis, D Basset, F Benoit-Vical, A Berry, N Bourgeois, F Conquere de Monbrison, P Delaunay, J Delmont, K Ezzedine, B Faugere, C Garabedian, E Garnotel, C Lollivier, D Malvy, P Marty, D Maubon, G Menard, P Millet, P Minodier, Montaut, A Mottard, P Munier, P Parola, R Piarroux, S Picot, T Pistone, C Pomares-Estran, J Puyhardy, D Raffenot, M-C Receveur, R Saidi, H Savini, F Simon, S Vedy.

## Author details

<sup>1</sup>Unité de Parasitologie, Département d'Infectiologie de Terrain, Institut de Recherche Biomédicale des Armées, Marseille, France. <sup>2</sup>Aix Marseille Université, Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, UM 63, CNRS 7278, IRD 198, Inserm 1095, Marseille, France. <sup>3</sup>Centre National de Référence du Paludisme, Marseille, France. <sup>4</sup>Equipe Résidente de Recherche en Infectiologie Tropicale, Institut de Recherche Biomédicale des Armées, Hôpital d'Instruction des Armées Laveran, Marseille,

France. <sup>5</sup>Direction Inter-Armées du Service de Santé, Cayenne, Guyane, France. <sup>6</sup>Laboratoire de Parasitologie, Institut Pasteur de la Guyane, Cayenne, Guyane, France. <sup>7</sup>Fédération des Laboratoires, Hôpital d'Instruction des Armées Saint Anne, Toulon, France. <sup>8</sup>Unité de Parasitologie et d'Entomologie, Département des Maladies Infectieuses, Institut de Recherche Biomédicale des Armées, Brétigny sur Orge, France.

Received: 7 October 2014 Accepted: 26 January 2015

Published online: 05 February 2015

## References

- Smithuis F, Kyaw MK, Phe O, Aye KZ, Htet L, Barends M, et al. Efficacy and effectiveness of dihydroartemisinin-piperazine versus artesunate-mefloquine in falciparum malaria: an open label randomized comparison. *Lancet*. 2006;367:2075-85.
- Thang NX, Trung TN, Phong NC, Quang HH, Dai B, Shanks GD, et al. The efficacy and tolerability of artemisinin-piperazine (Artequick) versus artesunate-amodiaquine (Coarsucam) for the treatment of uncomplicated *Plasmodium falciparum* malaria in south-central Vietnam. *Malar J*. 2012;11:217.
- Sylla K, Abiola A, Tine RCK, Faye B, Sow D, Ndiaye JL, et al. Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance. *Malar J*. 2013;13:598.
- Yavo W, Faye B, Kuete T, Djohan V, Oga SA, Kassi RR, et al. Multicentric assessment of the efficacy and tolerability of dihydroartemisinin-piperazine compared to artemether-lumefantrine in the treatment of uncomplicated *Plasmodium falciparum* malaria in sub-Saharan Africa. *Malar J*. 2011;10:198.
- Yeka A, Tibenderana J, Achan J, D'Alessandro U, Talisuna AO. Efficacy of quinine, artemether-lumefantrine and dihydroartemisinin-piperazine as rescue treatment for uncomplicated malaria in Ugandan children. *PLoS One*. 2013;8:53772.
- Agarwal A, McMorrow M, Onyango P, Otieno K, Odero C, Williamson J, et al. A randomized trial of artemether-lumefantrine and dihydroartemisinin-piperazine in the treatment of uncomplicated malaria among children in western Kenya. *Malar J*. 2013;12:254.
- Yeka A, Dorsey G, Kanya MR, Talisuna A, Lugemwa M, Rwakimari JB, et al. Artemether-lumefantrine versus dihydroartemisinin-piperazine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. *PLoS One*. 2008;3:2390.
- Kanya MR, Yeka A, Burkirwa H, Lugemwa M, Rwakimari JB, Staedke SG, et al. Artemether-lumefantrine versus dihydroartemisinin-piperazine for treatment of malaria: a randomized trial. *PLoS Clin Trials*. 2007;2:e20.
- Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Séré Y, Rosenthal PJ, et al. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperazine for the treatment of uncomplicated *Plasmodium falciparum* malaria in Burkina-Faso. *Clin Infect Dis*. 2007;45:1453-61.
- Hasugian AR, Purba HLE, Kenangalem E, Wuwung RM, Ebsworth EP, Maristela R, et al. Dihydroartemisinin-piperazine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug resistant *Plasmodium falciparum* and *Plasmodium vivax* malaria. *Clin Infect Dis*. 2008;44:1067-74.
- Pasaribu AP, Chokeyindachai W, Sirivichayakul C, Tanomsing N, Chavez I, Tjitra E, et al. A randomized comparison of Dihydroartemisinin-Piperazine and Artesunate-Amodiaquine combined with Primaquine for radical treatment of vivax malaria in Sumatera, Indonesia. *J Infect Dis*. 2013;208:1906-13.
- Leang R, Barrette A, Mey Bouth D, Menard D, Abdur R, Duong S, et al. Efficacy of dihydroartemisinin-piperazine for treatment of uncomplicated *Plasmodium falciparum* and *Plasmodium vivax* in Cambodia, 2008 to 2010. *Antimicrob Agents Chemother*. 2013;57:818-26.
- Saunders DL, Vanachayangkul P, Lon C. Dihydroartemisinin-piperazine failure in Cambodia. *N Engl J Med*. 2014;371:484-5.
- Thriemer K, Van Hong N, Rosanas-Urgell A, Ha DM, Pockele E, Guetens P, et al. Delayed parasite clearance after treatment with dihydroartemisinin-piperazine in *Plasmodium falciparum* malaria patients in Central Vietnam. *Antimicrob Agents Chemother*. 2014;58:7049-55.
- Pascual A, Madamet M, Bertaux L, Amalvict R, Benoit N, Travers D, et al. In vitro piperazine susceptibility is not associated with the *Plasmodium falciparum* chloroquine resistance transporter gene. *Malar J*. 2013;12:431.
- Pascual A, Parola P, Benoit-Vical F, Simon F, Malvy D, Picot S, et al. Ex vivo activity of the ACT new components pyronaridine and piperazine in

- comparison with conventional ACT drugs against isolates of *Plasmodium falciparum*. *Malar J.* 2012;11:45.
17. Basco LK, Ringwald P. In vitro activities of piperazine and other 4-aminoquinolines against clinical isolates of *Plasmodium falciparum* in Cameroon. *Antimicrob Agents Chemother.* 2003;47:1391–4.
  18. Okombo J, Abdi Al, Kiara SM, Mwai L, Pole L, Sutherland CJ, et al. Repeat polymorphisms in the low-complexity regions of *Plasmodium falciparum* ABC transporters and associations with *in vitro* antimalarial responses. *Antimicrob Agents Chemother.* 2013;57:6196–204.
  19. Okombo J, Kiara SM, Mwai L, Pole L, Ohuma E, Ochola LI, et al. Baseline *in vitro* activities of the antimalarials pyronaridine and methylene blue against *Plasmodium falciparum* isolates from Kenya. *Antimicrob Agents Chemother.* 2012;56:1105–7.
  20. Mwai L, Kiara SM, Abdurhaman A, Pole L, Rippert A, Diriye A, et al. In vitro activities of piperazine, lumefantrine, and dihydroartemisinin in Kenyan *Plasmodium falciparum* isolates and polymorphisms in *pfprt* and *pfmdr1*. *Antimicrob Agents Chemother.* 2009;55:5069–73.
  21. Issaka M, Salissou A, Arzika I, Guillebaud J, Maazou A, Specht S, et al. *Ex vivo* responses of *Plasmodium falciparum* clinical isolates to conventional and new antimalarial drugs in Niger. *Antimicrob Agents Chemother.* 2013;57:3415–9.
  22. Quashie NB, Duah NO, Abuaku B, Quaye L, Ayanful-Torgby R, Akwoviah GA, et al. A SYBR Green 1-based *in vitro* test of susceptibility of Ghanaian *Plasmodium falciparum* clinical isolates to a panel of anti-malarial drugs. *Malar J.* 2013;12:450.
  23. Nsoby SL, Kiggundu M, Nanyunja S, Joloba M, Greenhouse B, Rosenthal PJ. *In vitro* sensitivity of *Plasmodium falciparum* to different antimalarial drugs in Uganda. *Antimicrob Agents Chemother.* 2010;54:1200–6.
  24. Hao M, Jia D, Li Q, He Y, Yuan L, Xu S, et al. *In vitro* sensitivities of *Plasmodium falciparum* isolates from the China-Myanmar border to piperazine and association with polymorphisms in candidate genes. *Antimicrob Agents Chemother.* 2013;57:1723–9.
  25. Barends M, Jaidee A, Khaohirun N, Singhasivanon P, Nosten F. *In vitro* activity of ferroquine (SSR 97193) against *Plasmodium falciparum* isolates from the Thai-Burmese border. *Malar J.* 2007;6:81.
  26. Lim P, Dek D, Try V, Eastman RT, Chy S, Sreng S, et al. *Ex vivo* susceptibility of *Plasmodium falciparum* to antimalarial drugs in Western, Northern, and Eastern Cambodia, 2011–2012: Association with molecular markers. *Antimicrob Agents Chemother.* 2013;57:5277–83.
  27. Marfurt J, Chalfein F, Prayoga P, Wabiser F, Kenangalem E, Piar KA, et al. *Ex vivo* drug susceptibility of ferroquine against chloroquine-resistant isolates of *Plasmodium falciparum* and *P. vivax*. *Antimicrob Agents Chemother.* 2011;55:4461–4.
  28. Wong RPM, Lautu D, Tavul L, Hackett SL, Siba P, Karunajeewa HA, et al. *In vitro* sensitivity of *Plasmodium falciparum* to conventional and novel antimalarial drugs in Papua New Guinea. *Trop Med Int Health.* 2010;15:342–9.
  29. Looareesuwan S, Kyle DE, Vivaran C, Vanijanonta S, Wilairatana P, Wernsdorfer WH. Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand. *Am J Trop Med Hyg.* 1996;54:205–9.
  30. Tshetu AK, Gaye O, Kayentao K, Thompson R, Bhatt KM, Sesay SS, et al. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated *Plasmodium falciparum* malaria: a randomised non-inferiority trial. *Lancet.* 2010;375:1457–67.
  31. Kayentao K, Doumbo OK, Péneli LK, Offianan AT, Bhatt KM, Kimani J, et al. Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with *Plasmodium falciparum* malaria: a randomized controlled trial. *Malar J.* 2012;11:364.
  32. Rueangweerayut R, Phyto AP, Uthaisin C, Poravuth Y, Binh TQ, Tinto H, et al. Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. *N Engl J Med.* 2012;366:1298–309.
  33. Elueze EI, Croft SL, Warhurst DC. Activity of pyronaridine and mepracrine against twelve strains of *Plasmodium falciparum in vitro*. *J Antimicrob Chemother.* 1996;37:511–8.
  34. Pradines B, Briolant S, Henry M, Oeuvery C, Baret E, Amalvict R, et al. Absence of association between pyronaridine *in vitro* responses and polymorphisms in genes involved in quinoline resistance in *Plasmodium falciparum*. *Malar J.* 2010;9:337.
  35. Ringwald P, Moukoko Eboumbou CE, Bickii J, Basco LK. *In vitro* activities of pyronaridine, alone and in combination with other antimalarial drugs, against *Plasmodium falciparum*. *Antimicrob Agents Chemother.* 1999;43:1525–7.
  36. Pradines B, Mabika Mamfoumbi M, Parzy D, Owono Medang M, Lebeau C, Mourou Mbina JR, et al. *In vitro* susceptibility of African isolates of *Plasmodium falciparum* from Gabon to pyronaridine. *Am J Trop Med Hyg.* 1999;60:105–8.
  37. Kurth F, Pongratz P, Bédard S, Mordmüller B, Kreamsner PG, Ramharter M. *In vitro* activity of pyronaridine against *Plasmodium falciparum* and comparative evaluation of anti-malarial drug susceptibility assays. *Malar J.* 2009;8:79.
  38. Pradines B, Tall A, Parzy D, Spiegel A, Fusai T, Hienne R, et al. *In vitro* activity of pyronaridine and amodiaquine against African isolates (Senegal) of *Plasmodium falciparum* in comparison with standard antimalarial agents. *J Antimicrob Chemother.* 1998;42:333–9.
  39. Pradines B, Tall A, Ramiandrasoa F, Spiegel A, Sokhna C, Fusai T, et al. *In vitro* activity of iron-binding compounds against Senegalese isolates of *Plasmodium falciparum*. *J Antimicrob Chemother.* 2006;57:1093–9.
  40. Price RN, Marfurt J, Chalfein F, Kenangalem E, Piera KA, Tjitra E, et al. *In vitro* activity of pyronaridine against multidrug-resistant *Plasmodium falciparum* and *Plasmodium vivax*. *Antimicrob Agents Chemother.* 2010;54:5146–50.
  41. Lambros C, Vanderberg JP. Synchronization of *Plasmodium falciparum* erythrocytic stages in culture. *J Parasitol.* 1979;65:418–20.
  42. Bogreau H, Renaud F, Bouchiba H, Durand P, Assi SB, Henry MC, et al. Genetic diversity and structure of African *Plasmodium falciparum* populations in urban and rural areas. *Am J Trop Med Hyg.* 2006;74:953–9.
  43. Henry M, Diallo I, Bordes J, Ka S, Pradines B, Diatta B, et al. Urban malaria in Dakar, Senegal: chemosusceptibility and genetic diversity of *Plasmodium falciparum* isolates. *Am J Trop Med Hyg.* 2006;75:146–51.
  44. Richardson S, Green PJ. On Bayesian analysis of mixtures with an unknown number of components (with discussion). *J Roy Stat Soc.* 1997;B59:731–92.
  45. Cappé O, Robert CP, Rydén T. Reversible jump, birth-and-death and more general continuous time Markov chain Monte Carlo samplers. *J Roy Stat Soc.* 2003;B65:679–700.
  46. Diebolt J, Robert CP. Estimation of finite mixture distributions through Bayesian sampling. *J Roy Stat Soc.* 1994;56:363–75.
  47. Jasra A, Holmes CC, Stephens DA. Markov chain Monte Carlo methods and the label switching problem in Bayesian mixture modeling. *Stat Sci.* 2005;20:50–67.
  48. Sibley CH, Barnes KI, Plowe CV. The rationale and plan for creating a world antimalarial resistance network (WARN). *Malar J.* 2007;6:118.
  49. Sibley CH, Barnes KI, Watkins WM, Plowe CV. A network to monitor antimalarial drug resistance: a plan for moving forward. *Trends Parasitol.* 2008;24:43–8.
  50. Bacon DJ, Jambou R, Fandeur T, Le Bras J, Wongsrichanalai C, Fukuda MM, et al. World Antimalarial Resistance Network (WARN) II: *in vitro* antimalarial drug susceptibility. *Malar J.* 2007;6:120.
  51. Plowe CV, Rooper C, Barnwell JW, Happi CT, Joshi HH, Mbacham W, et al. World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. *Malar J.* 2007;6:121.
  52. Briolant S, Baragatti M, Parola P, Simon F, Tall A, Sokhna C, et al. Multinomial *in vitro* distribution model suitable for the distribution of *Plasmodium falciparum* chemosusceptibility to doxycycline. *Antimicrob Agents Chemother.* 2009;53:688–95.
  53. Gaillard T, Briolant S, Houzé S, Baragatti M, Wurtz N, Hubert V, et al. *Pfprt* and *pfmdt* copy numbers as predictive molecular markers of decreased *ex vivo* doxycycline susceptibility in imported *Plasmodium falciparum* malaria. *Malar J.* 2013;12:414.
  54. Divo AA, Geary TG, Jensen JB. Oxygen- and time-dependent effects of antibiotics and selected mitochondrial inhibitors on *Plasmodium falciparum* in culture. *Antimicrob Agents Chemother.* 1985;27:21–7.
  55. Pascual A, Basco LK, Baret E, Amalvict R, Travers D, Rogier C, et al. Use of the atmospheric generators for capnophilic bacteria Genbag-CO2 for the evaluation of *in vitro Plasmodium falciparum* susceptibility to standard anti-malarial drugs. *Malar J.* 2011;10:8.
  56. Fall B, Diawara S, Sow K, Baret E, Diatta B, Fall KB, et al. *Ex vivo* susceptibility of *Plasmodium falciparum* isolates from Dakar, Senegal, to seven standard anti-malarial drugs. *Malar J.* 2011;10:310.
  57. Wein S, Mynadier M, Tran Van Ba C, Cerdan R, Peyrottes S, Fraisse L, et al. Reliability of antimalarial sensitivity tests depends on drug mechanisms of action. *J Clin Microbiol.* 2010;48:1651–60.
  58. Pradines B, Rogier C, Fusai T, Mosnier J, Daries W, Barret E, et al. *In vitro* activities of antibiotics against *Plasmodium falciparum* are inhibited by iron. *Antimicrob Agents Chemother.* 2001;45:1746–50.



59. Sidhu ABS, Sun Q, Nkrumah LJ, Dunne MW, Sacchetti JC, Fidock DA. In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. *J Biol Chem.* 2007;282:2494–504.
60. Briolant S, Parola P, Fusai T, Madamet-Torrentino M, Baret E, Mosnier J, et al. Influence of oxygen on asexual blood cycle and susceptibility of *Plasmodium falciparum* to chloroquine: requirement of standardized in vitro assay. *Malar J.* 2007;6:44.
61. Pradines B, Tall A, Fusai T, Spiegel A, Hienne R, Rogier C, et al. In vitro activities of benflumetol against 158 Senegalese isolates of *Plasmodium falciparum* in comparison with those of standard antimalarial drugs. *Antimicrob Agents Chemother.* 1999;43:418–20.
62. Muangnoicharoen S, Johnson DJ, Looareesuwan S, Krudsood S, Ward SA. Role of known molecular markers of resistance in the antimalarial potency of piperazine and dihydroartemisinin in vitro. *Antimicrob Agents Chemother.* 2009;53:1362–6.
63. Hofer S, Brun R, Maerki S, Matile H, Scheurer C, Wittlin S. In vitro assessment of the pharmacodynamics properties of DB75, piperazine, OZ277 and OZ401 in cultures of *Plasmodium falciparum*. *J Antimicrob Chemother.* 2008;62:1061–4.
64. Tinto H, Bonkian LN, Nana LA, Yerbanga I, Lingani M, Kazienga A, et al. Ex vivo anti-malarial drugs sensitivity profile of *Plasmodium falciparum* field isolates from Burkina Faso five years after the national policy change. *Malar J.* 2014;13:207.
65. Tyner SD, Lon C, Se Y, Bethell D, Socheat D, Noedl H, et al. Ex vivo drug sensitivity profiles of *Plasmodium falciparum* field isolates from Cambodia and Thailand, 2005 to 2010, determined by a histidine-rich protein assay. *Malar J.* 2012;11:198.
66. Sawa P, Shekalaghe SA, Drakeley CJ, Sutherland CJ, Mweresa CK, Baidjoe AY, et al. Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperazine: A randomized trial. *J Infect Dis.* 2013;207:1637–45.
67. Onyamboko MA, Fanello CI, Wongsanen K, Tarning J, Cheah PY, Tshefu KA, et al. Randomized comparison of the efficacies and tolerabilities of three artemisinin-based combination treatments for children with acute *Plasmodium falciparum* malaria in the Democratic Republic of the Congo. *Antimicrob Agents Chemother.* 2014;58:5528–36.
68. Wanzira H, Kakuru A, Arinaitwe E, Bigira V, Muhindo MK, Conrad M, et al. Longitudinal outcomes in a cohort of Ugandan children randomized to artemether-lumefantrine versus dihydroartemisinin-piperazine for the treatment of malaria. *Clin Infect Dis.* 2014;59:509–16.
69. Naing C, Raclou V, Whittaker MA, Aung K, Reid SA, Mak JW, et al. Efficacy and safety of dihydroartemisinin-piperazine for treatment of *Plasmodium vivax* malaria in endemic countries: meta-analysis of randomized controlled studies. *PLoS One.* 2013;8:78819.
70. Henrich PP, O'Brien C, Sáenz FE, Cremers S, Kyle DE, Fidock DA. Evidence for pyronaridine as a highly effective partner drug for treatment of artemisinin-resistant malaria in a rodent model. *Antimicrob Agents Chemother.* 2014;58:183–95.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

